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Rationale: Smoking-induced chronic obstructive pulmonary disease (COPD) is associated with acquired systemic
cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. Recently, sweat evaporimetry has been
shown to efficiently measure β-adrenergic sweat rate and specifically quantify CFTR function in the secretory coil of
the sweat gland.
Objectives: To evaluate the presence and severity of systemic CFTR dysfunction in smoking-related lung disease
using sweat evaporimetry to determine CFTR-dependent sweat rate.
Methods: We recruited a cohort of patients consisting of healthy never smokers (N = 18), healthy smokers (12),
COPD smokers (25), and COPD former smokers (12) and measured β-adrenergic sweat secretion rate with
evaporative water loss, sweat chloride, and clinical data (spirometry and symptom questionnaires).
Measurements and main results: β-adrenergic sweat rate was reduced in COPD smokers (41.9 ± 3.4, P < 0.05, ± SEM)
and COPD former smokers (39.0 ± 5.4, P < 0.05) compared to healthy controls (53.6 ± 3.4). Similarly, sweat chloride
was significantly greater in COPD smokers (32.8 ± 3.3, P < 0.01) and COPD former smokers (37.8 ± 6.0, P < 0.01) vs.
healthy controls (19.1 ± 2.5). Univariate analysis revealed a significant association between β-adrenergic sweat
rate and female gender (β = 0.26), age (−0.28), FEV1% (0.35), dyspnea (−0.3), and history of smoking (−0.27;
each P < 0.05). Stepwise multivariate regression included gender (0.39) and COPD (−0.43) in the final model
(R2 = 0.266, P < 0.0001).
Conclusions: β-adrenergic sweat rate was significantly reduced in COPD patients, regardless of smoking status,
reflecting acquired CFTR dysfunction and abnormal gland secretion in the skin that can persist despite smoking
cessation. β-adrenergic sweat rate and sweat chloride are associated with COPD severity and clinical symptoms,
supporting the hypothesis that CFTR decrements have a causative role in COPD pathogenesis.Introduction
The defining feature of chronic obstructive pulmonary
disease (COPD) is airflow limitation, although it is rec-
ognized that the disease exhibits heterogeneous patho-
logic features in the lung, including mucus retention
[1,2]. Acquired cystic fibrosis transmembrane conduct-
ance regulator (CFTR) dysfunction caused by cigarette
smoke exposure has been implicated as a potential factor* Correspondence: smrowe@uab.edu
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in the mucociliary transport apparatus [3-8]. Cigarette
smoke inhibits CFTR activity in airway cells in vitro
[3,5,6,9,10], and in human subjects with and without
COPD [3,9], indicating a potential therapeutic target to
combat mucus stasis in the disease. Further studies have
shown that smoking-related CFTR dysfunction and its
downstream effects, such as depleted airway surface li-
quid depth or delayed mucociliary transport, can be re-
versed in vitro by augmentation of CFTR dependent
anion transport by the CFTR potentiator ivacaftor [9] or
by osmotic loading with hypertonic saline [10], providingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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vance of this pathway.
While several studies have established the presence of
acquired CFTR dysfunction in the COPD airway, it has
only been recently reported that the defect in CFTR
function may extend beyond the airways. Raju et al. re-
cently described a cohort of current and former smokers
with and without COPD who each exhibited elevated sweat
chloride when compared with healthy never smokers, sug-
gesting a decrement in CFTR function outside the respira-
tory tract [11]. In addition, this study demonstrated that
inhaled whole cigarette smoke decreased CFTR activity in
the distal ileum of mice, confirming similar findings from
rectal biopsy samples of human smokers [11]. These find-
ings support the notion that CFTR decrements may be a
systemic phenomenon in smoking related diseases.
An effort to detect the degree of systemic impairment
of CFTR in acquired disorders may be limited by trad-
itional assays such as quantitative pilocarpine iontophor-
esis (QPIT) which may not be maximally sensitive towards
detecting modest decrement in CFTR function [12]. Fur-
ther, QPIT measures the impact on the absorptive activity
of CFTR, rather than the secretory activity, which may be
a substantial contributor to pulmonary pathology [13]. Re-
cently Quinton and colleagues developed an assay that
may be more sensitive for detecting a modest decrement
in CFTR function by using quantitative evaporimetry to
measure ß-adrenergic-induced sweat secretion rate [14].
The assay provides a direct assessment of CFTR activity in
the sweat gland, which may correlate better with secretory
gland function, including airway submucosal glands, which
are markedly abnormal in CF and could be a significant
contributor to pathogenesis in COPD [15,16]. To confirm
our hypothesis that acquired CFTR dysfunction can be de-
tected beyond the airway and test whether the defect alters
function of the glandular compartment, we used this assay
in patients without CFTR mutations to quantify glandular
CFTR activity while also assessing the phenotypic expres-
sion of COPD. Our results indicate a systemic reduction in
CFTR function in COPD patients as detected by both eva-
porimetry and sweat chloride, which has significant physio-
logic and clinical implications.
Methods and materials
Recruitment of human subjects
Protocols were approved by the University of Alabama
at Birmingham’s Institutional Review Board and all subjects
provided written informed consent (Approval F101110001).
Subjects age 40–75 years were eligible. Subjects were cate-
gorized into one of four eligible groups: (1) healthy never
smokers; (2) healthy smokers with ≥ 10 pack-year smoking
history who continued to smoke more than 10 cigarettes
per day; (3) COPD patients with ≥ 10 pack-years who con-
tinued to smoke more than 10 cigarettes daily; (4) COPDpatients with ≥ 10 pack years who have remained abstinent
from tobacco for more than 1 year. Subjects were recruited
prospectively and disease status was not assigned until after
enrollment. More detailed inclusion and exclusion criteria
are detailed online (Additional file 1).
Phenotype characterization
The presence of chronic bronchitis (as assessed by the
Medical Research Council definition of cough and spu-
tum present most days of three months in two consecu-
tive years) [17] and COPD symptom severity (measured
by the Breathlessness Cough and Sputum Scale ques-
tionnaire) were documented on each subject [18]. COPD
severity was also measured by components of the BODE
index (body mass index, obstruction (FEV1% predicted),
and dyspnea (Modified Medical Research Council (MMRC)
Questionnaire)) [19]. Cumulative cigarette exposure
was recorded as total lifetime pack-years smoked and
current cigarette use. Smoking status of never smokers
and COPD former smokers was confirmed with urine co-
tinine analysis.
Sweat secretion test
We performed sweat evaporimetry to measure exocrine
gland function of the sweat gland on all subjects [14].
All evaporimetry tracings were analyzed by a single
blinded investigator. Sweat rates were calculated as the
maximal stable rate observed after β-adrenergic injection
less the lowest observed rate after the preceding atropine
injection, as previously described [14]. The rate of evap-
orative water loss (kg water loss/m2/h) is expressed as
evaporimeter units.
Genetic testing
Genetic testing (50 mutation analysis) for CFTR muta-
tions was performed on all participants by using a com-
mercially accredited facility (Baylor Medical Genetics,
Houston, TX). Patients with a CFTR mutation were ex-
cluded from the analysis.
Sweat chloride testing
Sweat chloride was measured by quantitative pilocarpine
iontophoresis via the Macroduct (Westcor Inc., Logan,
UT) collection system as previously reported [11,20,21].
Statistics
Sweat rate, sweat chloride, and subgroup analyses were
compared using ANOVA. Post-hoc tests for multiple
comparisons were calculated using Fisher’s least signifi-
cant difference if ANOVA was significant. All statistical
tests were two-sided and performed at a 5% significance
level using GraphPad Prism (La Jolla, CA). Error bars des-
ignate SEM unless indicated otherwise. Regression ana-
lyses were performed using SPSS (IBM, Armonk, NY);
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Results
We recruited 87 subjects and 20 were excluded based
on presence of CFTR genetic mutation, unsuccessful
sweat rate assay, or inadequate disease categorization
based on history or spirometry (Figure 1). The summary
of the patients included in the final analysis is presented
in Table 1. There was a slight predominance of males in
each group but the balance was not significantly differ-
ent in any cohort. The mean age of the COPD patients
was significantly greater than the other groups. As ex-
pected, the BCSS and MMRC scores were significantly
greater and FEV1 significantly lower in the COPD cohorts.
Evaporimetry was successfully performed on 67 eligible
subjects. Representative evaporimeter tracings are shown
in Figure 2A. In COPD subjects, there was a significant
decrement in the β-adrenergic-induced sweat rate, but
not the cholinergic sweat rate. The mean β-adrenergicFigure 1 Subject disposition.sweat rate comparisons are presented in Figure 2B. The
mean (± standard error) β-adrenergic sweat rate for
healthy, never smokers was 53.6 ± 3.3. This rate was sig-
nificantly lower in COPD smokers (41.9 ± 3.4; P < 0.05),
and COPD former smokers (39.0 ± 5.4; P < 0.05). There
was a trend toward reduced sweat rate in healthy smokers,
51.3 ± 4.4, when compared with healthy never smokers,
but this difference was not statistically significant.
Sweat chloride testing revealed a similar pattern of ab-
normalities as detected by β-adrenergic sweat rate testing
(Figure 3). The mean sweat chloride for healthy never
smokers was 19.1 ± 2.4 whereas the concentrations in
COPD smokers (32.8 ± 3.3; P < 0.01) and COPD former
smokers (37.8 ± 6.0; P < 0.01) were significantly increased
and generally consistent with previous results [11]. There
was a trend towards elevated sweat chloride in healthy
smokers (mean of 26.38 ± 4.19) but this was not statisti-
cally different than the control group.
Sweat chloride and ß-adrenergic sweat rate did not
correlate on an individual basis when the entire study













P Value Pairwise with P < 0.05
(ANOVA)
N 18 12 25 12
Age (mean, SD) 47 ± 9 52 ± 8 58 ± 9 68 ± 8 < 0.001 HNS-CS, HNS-CFS, HS-CFS, CS-CFS
Gender N (%)
Male 11 (61%) 6 (50%) 19 (76%) 9 (75%) 0.387
Female 7 (39%) 6 (50%) 6 (24%) 3 (25%)
Race N (%)
Caucasian 13 (72%) 4 (27%) 14 (56%) 8 (67%) 0.185
African-American 5 (28%) 8 (63%) 11 (44%) 4 (33%)








1.03 ± 0.10 0.97 ± 0.12 0.60 ± 0.16 0.41 ± 0.18 < 0.001 HNS-CS, HNS-CFS, HS-CS,
HS-CFS, CS-CFS
Pack-years (Mean, SD) 0 31.08 ± 14 38 ± 19 44 ± 19 <0.0001 HNS-HS, HNS-CS, HNS-CFS
MMRC (Mean, SD) 0.06 ± .236 0.83 ± .577 1.96 ± 1.197 2.83 ± 1.03 < 0.001 HNS-HS, HNS-CS, HNS-CFS,
HS-CS, HS-CFS, CS-CFS
BCSS (Mean, SD) 0.06 ± 0.236 0.75 ± 0.965 3.46 ± 3.007 2.67 ± 2.43 < 0.001 HNS-CS, HNS-CFS, HS-CS,
HS-CFS
MMRC =Modified Medical Research Council criteria; BCSS = Breathlessness, Cough and Sputum Scale. The mean and standard deviation for clinical characteristics
for our patient cohorts are provided. Post-hoc pairwise analysis was done using least significant difference as appropriate. HNS = Healthy Never Smokers;
HS = Healthy Smokers; CS = COPD Active Smokers; CFS = COPD Former Smokers.
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says were compared after grouping patients based on
disease group, a linear correlation was readily apparent
(Figure 4B; P < 0.05, R2 = 0.93).
Regression analysis was performed to evaluate which
clinical parameters were associated with reduced CFTR-
dependent sweat secretion (Table 2). As described previ-
ously, females exhibited lower sweat rates than males
[14]. Univariate analysis also indicated a negative associ-
ation with age. Abnormal sweat rate was also associated
with features of COPD severity, including dyspnea as
assessed by MMRC and reduced FEV1%, as well as with
any history of smoking. Stepwise multivariate regression
was performed with all available clinical covariates. The
final model included gender (β = 0.39) and COPD
(β = −0.43), indicating a pronounced effect of COPD on
β-adrenergic sweat rate, even when controlled for gender
(R2 = 0.266, P < 0.0001). An adjusted analysis with gender
included as a covariate demonstrated that COPD pa-
tients exhibited significantly lower CFTR-dependent
sweat rate than non-COPD subjects (Table 3). An ad-
justed analysis that included age and gender did not sig-
nificantly alter conclusions.
We also analyzed the relationship between clinical pa-
rameters and sweat chloride. Univariate analysis revealed a
significant relationship between sweat chloride abnormalityand age, COPD, FEV1%, COPD symptoms, smoking status
and intensity, and decreased BMI (Table 4). These findings
were largely consistent with a previous study [11]. Multiple
linear regression using the stepwise approach included
only smoking intensity (pack-years) in the final model
(R2 = 0.185, P < 0.001). The effect of smoking intensity
persisted (β = 0.280, R2 = 0.224, P = 0.051), even when
age was included as a covariate, excluding its contri-
bution to the abnormality. For further confirmation
that age was not contributing to our findings, we ex-
amined the relationship between age and sweat chloride
in normal non-smoking controls using all individuals in
our COPD study database (N = 33), including those
presented in a previous publication [11]. We found
no significant relationship between age and sweat chloride
(β = 0.062, P = 0.731, N = 33). Given this effect, for every
10 years of age, sweat chloride would only be expected to
increase by 0.6 mmol/L, an insufficient magnitude to ex-
plain our results based on age alone.
Discussion
We describe the first use of ß-adrenergic sweat secre-
tion to detect CFTR dysfunction in individuals with
smoking-related lung disease providing strong evidence
that COPD is associated with acquired CFTR dysfunc-
tion in extra-pulmonary organs. β-adrenergic-induced
Figure 2 Systemic CFTR dysfunction in COPD subjects as demonstrated by β-Adrenergic sweat secretion rate. (A) Representative sweat
secretion assay tracings of a healthy never smoker (solid) and a COPD patient (dotted). Evaporative water loss is measured continuously following
injection of (a1) atropine, (c) carbachol, (a2) atropine again, and (b) β-adrenergic cocktail stimulus. The stable β-adrenergic stimulated sweat
secretion rate is marked with a bar. (B) Summary data plotting maximal β-adrenergic sweat rate for each individual subject. *P < 0.05.
Figure 3 Sweat chloride abnormality in COPD subjects.
Quantitative pilocarpine iontophoresis measured concurrently to the
β-adrenergic sweat test in each subject. **P < 0.01.
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diagnostic option in those who possess modest CFTR
abnormalities [14]. The use of evaporimetry in this set-
ting allows assessment of exocrine function and may
carry greater clinical significance compared to traditional
testing since it has been suggested that CFTR abnormal-
ities in glandular epithelia and other secretory compart-
ments are highly relevant to lung pathophysiology [14].
Acquired CFTR abnormalities in the sweat gland epithe-
lium are consistent with altered sweat chloride identified
in smokers and COPD patients derived from a larger co-
hort of individuals with the exact same clinical inclusion
criteria [11].
Our observations have important implications on the
relationship between CFTR dysfunction and COPD
pathogenesis. The results demonstrate that CFTR dys-
function is present in a subset of COPD patients and
can be readily detected beyond the airway using a simple
and inexpensive clinical test in both current and former
Figure 4 Relationship between sweat chloride and β-adrenergic sweat rate. Sweat chloride (x-axis) and β-adrenergic sweat rate (y-axis) are
plotted for each individual subject (A) and by disease group (B). Regression line shown in (B) was statistically significant (R2 = 0.933, P < 0.05).
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strated that CFTR function can recover in the nasal epi-
thelium [7,9] and that nasal mucociliary clearance can
recover following smoking cessation in healthy smokers
without COPD [22], our results suggest CFTR deficits
can be sustained in individuals with a diagnosis ofTable 2 Univariate regression analysis in relation to
β-adrenergic sweat rate
Beta 95% Confidence intervals P-value
Gender 0.259 2.09, 19.23 0.016
Age −0.282 −0.812, -.069 0.021
Race 0.062 −6.40, 10.64 0.621
BCSS −0.135 −2.71, 0.801 0.282
Bronchitis −0.148 −14.466, 3.635 0.236
FEV1 0.345 6.820, 35.08 0.004
MMRC −0.3 −6.877, -0.789 0.014
Pack years 0.017 0.257, 0.289 0.906
Active smoke −0.093 −11.570, 5.255 0.456
Ever smoke −0.271 −19.225, -1.233 0.026
BMI −0.02 −0.813, 0.691 0.872
Cigarette/day −0.188 0.651, 0.084 0.128
MMRC =Modified Medical Research Council criteria; BCSS = Breathlessness,
Cough and Sputum Scale; BMI = Body Mass Index.COPD. A similar finding was observed in our prior ana-
lysis which also included intestinal current measure-
ments of former smokers [11]; a trend was also seen in
the measurement of CFTR function in lower airways of
COPD former smokers [8]. Moreover, Bodas et al. re-
ported reduced CFTR expression was also observed in
the lungs of patients with emphysema despite smoking
cessation [23].
The current cohort indicates that the CFTR abnormality
is also associated with disease phenotype, further support-
ing a causal association. Sloane et al. demonstrated re-
duced CFTR–dependent nasal potential difference (NPD)
in COPD subjects, and that CFTR dysfunction was associ-
ated with symptoms of chronic bronchitis, even when
controlled for smoking [9]. This association was noted in





Healthy never smokers 54.47 ± 3.60 47.28, 61.65
Healthy smokers 53.64 ± 4.45 44.75, 62.53
COPD smokers 40.70 ± 3.07 ** 34.57, 46.83
COPD former smokers 37.93 ± 4.41** 29.13, 46.73
Mean ± SEM is presented for each group following adjustment for
gender. **P < 0.01.










Pack years 0.429 <0.001
Active smoker 0.183 0.149




MMRC =Modified Medical Research Council criteria; BCSS = Breathlessness,
Cough and Sputum Scale; BMI = Body Mass Index.
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lates with smoking intensity and chronic bronchitis symp-
toms [22]. These reports are consistent with the present
data that demonstrate an association between abnormal
sweat gland function and COPD symptoms (dyspnea), and
suggest sweat testing may be a feasible means to detect
individuals with CFTR-dependent abnormalities in physi-
ology due to COPD or cigarette smoking.
Persistence of CFTR dysfunction among COPD former
smokers suggests the presence of a sustained mediator
of CFTR dysfunction in COPD, a concept proposed by
Raju et al. [11], although the exact mechanism by which
reduced CFTR function is conferred in COPD is not yet
fully elucidated. It has been demonstrated that cigarette
smoke extract can have an impact on basolateral ion
transport [5], which in turn could impact CFTR function
at the airway surface by disrupting electrochemical gra-
dients. More recent work by Moran et al. suggests that
cigarette smoke can impact CFTR in a mechanism simi-
lar to CFTR inhibitors in the arylaminobenzoate class
and may affect CFTR via access through the cytosol, a
pathway consistent with entry via the systemic circula-
tion [24]. These findings provide further understanding
of how a tobacco constituent in the serum could affect
apical CFTR function, either within the airway or sweat
gland lumen.
While there may be many cigarette smoke constituents
that contribute to acquired CFTR dysfunction [25], one
such agent found to circulate in smokers was the cigarette
smoke constituent and inflammatory byproduct acro-
lein, a reactive aldehyde that directly inhibits CFTR
open channel probability in isolated membrane patches and
blocks CFTR mediated short-circuit current in epithelialmonolayers [11]. Interestingly, the effects of acrolein can
be sustained due to retention in tissue [26], and is known
to induce ER stress, which can alter CFTR expression
[27]. While a number of studies have established that
CFTR dysfunction can be induced in the airways in re-
sponse to direct insults from cigarette smoking [3,9,10]
(e.g. cadmium [25,28]), arsenic [29], hypoxia [4] or in-
flammatory byproducts (e.g. neutrophil elastase) [8,30],
whether these alternative mediators are also operative in
the systemic circulation has not yet been defined. Other
studies have elucidated potential serum biomarkers for
COPD including interleukin-6, C-reactive protein, tumor
necrosis factor-α, among others [31-33], which support
the notion that COPD causes a low-grade systemic in-
flammatory state. Similarly, systemic CFTR dysfunction
could explain phenotypic abnormalities more common in
individuals who smoke, such as reduced BMI [34], idio-
pathic pancreatitis [35], male infertility [36], and osteopor-
osis [37], since each of these are definitively linked to
CFTR physiology and are expressed in individuals with
varying degrees of genetic CFTR abnormality. Further
studies to define the pathogenic role of acquired systemic
CFTR dysfunction in this disease are needed to better
understand the role of this pathway.
Our study serves to validate recent applications of
sweat rate in humans with various severities of genetic
CFTR mutations since patients with smoke exposure or
COPD exhibit partial CFTR decrements akin to individ-
uals who are heterozygous for CFTR mutations. As in
prior studies, we used sweat chloride as a means to con-
firm the β-adrenergic sweat secretion assay. Though
sweat rate and sweat chloride did not correlate on an in-
dividual basis (Figure 4A), a linear relationship was ob-
served across disease groups (Figure 4B). While the lack
of correlation among individuals could be due to the
relatively small number of subjects in each group, recent
studies in CF have indicated that altered sweat chloride
and response to therapeutics are heterogeneous among
individuals [21,38]; poor correlation between CFTR bio-
markers (i.e. sweat chloride versus NPD) in the same in-
dividuals has also been problematic in these studies,
which may explain why a tighter relationship is not ap-
parent in this sample.
To further clarify the relationship between CFTR test-
ing methods, we compared sweat chloride and sweat
secretion rate to CFTR function measured by NPD testing
based on previously reported values among various CF
phenotypes (Figure 5) [14]. While each curve is non-linear,
each test is particularly sensitive at different extremes of
phenotypic severity. Interpolating CFTR function (as mea-
sured by NPD) for the subjects enrolled in our study, we
can estimate CFTR function in the various phenotypic
groups, which varied depending on the assay used. Based
on sweat chloride, the estimated CFTR function in COPD
Figure 5 Relationship between sweat tests and CFTR function estimated by nasal potential difference. (A) Based on previously reported
values from the literature, sweat chloride and β-adrenergic Sweat Rate are plotted against percent CFTR function as measured by nasal potential
difference (NPD). (B) Sweat chloride and evaporimetry data represented as percent normal sweat test from this study for COPD smokers (∇) and
COPD former smokers (Δ) are interpolated and plotted on each curve. CF-PI = pancreatic insufficient CF; CF-PS = pancreatic sufficient CF [12,14].
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estimated CFTR dysfunction was less severe (~90% of
normal). Whether differences in the manner that cigarette
smoking and COPD affect the secretory (sweat rate) ver-
sus absorptive (sweat chloride) compartments of the sweat
gland has physiologic implications will require further
study. Moreover, use of NPD represents only one of sev-
eral methods to extrapolate relative CFTR function, thus
estimates of absolute CFTR activity should be judged with
caution.
The limitations of this observational cohort study in-
clude the relatively small numbers of patients in each
cohort and the lack of age and gender matching despite
similar age limits in the inclusion criteria. This concern
is mitigated since the effect of COPD persists with use
of multiple regression to account for these differences
and consistency between two separate cohorts. Similarly,while age was related to sweat chloride abnormality on
univariate analysis, it was not significant in the multiple
regression model, suggesting the effect of smoking on
sweat chloride was the dominant factor; moreover, sweat
chloride was not related to age in a cohort of normal
non-smokers. Given the heterogeneous nature of COPD,
more study is needed to better classify disease pheno-
types to allow directed therapeutics, and to further ex-
plore the etiology for the persistent decrement in CFTR
function beyond the airway. Finally, our study provides
further impetus to test whether therapeutics that directly
or indirectly augment CFTR activity have a beneficial ef-
fect on patients with COPD, including those that have
stopped smoking but exhibit a sustained CFTR defect. If
successful, the results could have important implications
in COPD therapeutics and open a new approach to ad-
dress mucus stasis in the disease.
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